Jiangsu Xinrui

Jiangsu Xinrui Medical Technology is a leading Chinese healthcare company specializing in the development and manufacturing of advanced blood purification and hemodialysis systems. Founded in 2014 and headquartered in Changzhou, the company produces high-end synthetic membrane dialyzers, hemodiafiltration machines, and continuous renal replacement therapy (CRRT) equipment. Backed by prominent investors including Lilly Asia Ventures, Sequoia China, and IDG Capital, Xinrui aims to provide high-quality, domestically-produced alternatives to imported dialysis products. The company's core technology focuses on high-performance membrane materials and integrated dialysis control systems, positioning it as a key player in China's medical device localization strategy for end-stage renal disease.